-0.01 (-2.08%)
Dilution Risk
Revenue
56.33 K
R&D Expenses
793.98 K
Operating CF
-2.92 M
Total Assets
80.66 M
Total Liabilities
13.84 M
Equity
66.82 M
Cash Position
3.54 M
Monthly Burn
973.00 K
Runway
0.9 mo
Burn Trend
StableSEC Filing
May 15, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
NDA Submission example | NDA | — | Subscribe to access the data. | Small Molecules | Nervous System |
Dated clinical, regulatory & corporate events for Scienture Holdings, Inc.
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-03-13 | Arbli (losartan potassium) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-03-13 | Arbli (losartan potassium) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-03-13 | Arbli (losartan potassium) | PDUFA Date | PDUFA | Approved | – | – | – |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Scienture Holdings, Inc. has announced the commercial launch of REZENOPY™, the highest-dose FDA-approved naloxone nasal spray. The product is designed for emergency treatment of opioid overdoses and has begun nationwide distribution following the fulfillment of initial purchase orders. Scienture aims to expand market access and adoption through a dedicated sales team and payer coverage.
Read more →Scienture Holdings, Inc. announced the completion of manufacturing and upcoming shipments of REZENOPY™ (naloxone hydrochloride) Nasal Spray 10 mg to U.S. wholesalers, with commercial availability expected in August. This product is designed for emergency treatment of opioid overdoses and represents a significant opportunity in the $144 million naloxone market. The company has also expanded payer access to over 100 million lives, enhancing its market position.
Read more →Scienture Holdings, Inc. has announced significant advancements in the commercialization of Arbli™, including expanded payor coverage that now includes approximately 12.5 million additional covered lives. The company is focusing on increasing patient access through broader pharmacy networks and channel partnerships. Arbli™, a liquid formulation of losartan, aims to improve compliance among patients who have difficulty swallowing tablets.
Read more →Scienture Holdings, Inc. announced that its naloxone product, REZENOPY™, has been added to the formulary of a large national health plan, enhancing access for over 100 million covered lives. The product, which is the highest FDA-approved naloxone dose available, is set for commercial launch in mid-July 2026. Scienture is also expanding its sales team to support the product's rollout across various healthcare sectors.
Read more →Scienture Holdings, Inc. announced the granting of U.S. Patent No. 12,622,903 B2 for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, effective May 12, 2026, expiring February 5, 2041. This patent strengthens their intellectual property and supports their exclusive commercialization rights in the U.S. The product, approved by the FDA, aims to address the opioid overdose crisis.
Read more →Scienture Holdings, Inc. reported significant financial growth for Q1 2026, with revenue increasing by 449% year-over-year to approximately $56,000. The gross profit surged by 7900%, leading to a gross margin expansion to 95.6%. The company also secured key patents and financing to support its product portfolio and commercialization strategy. However, it reported a net loss of approximately $3.4 million.
Read more →Scienture Holdings has secured $11 million in non-dilutive debt financing to enhance its commercial efforts for its FDA-approved products, Arbli™ and REZENOPY™. The funds will also support the advancement of its R&D pipeline, which includes multiple therapeutic candidates. Company executives expressed confidence that this financing would help the company achieve profitability by 2027 and mentioned a focus on operational milestones. This strategic funding marks a significant step in the company's growth trajectory and commitment to patient care.
Read more →Scienture Holdings, Inc. announced the granting of a third patent for ARBLI™, its FDA-approved losartan potassium oral suspension. This patent, issued on April 21, 2026, extends intellectual property protection until October 2041. ARBLI™ offers a ready-to-use liquid formulation, enhancing patient compliance, particularly for those unable to swallow tablets. The product is positioned to capture significant market share in the $241 million U.S. losartan market.
Read more →Scienture Holdings, Inc. has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement of $1.00 per share. The company has until October 12, 2026, to achieve compliance. Scienture highlights its potential for growth with the upcoming launch of Arbli™, a novel FDA-approved hypertension treatment, and REZENOPY™, a naloxone nasal spray. However, the company acknowledges challenges in maintaining Nasdaq compliance standards.
Read more →Scienture Holdings, Inc. provided a comprehensive annual update highlighting significant progress in its pharmaceutical platform. Key achievements include the successful launch of Arbli™, an FDA-approved liquid formulation of losartan, and the strategic acquisition of REZENOPY™, aimed at addressing opioid overdose. The company reported a 216% increase in net revenue year-over-year, despite a net loss due to a one-time impairment charge. Looking ahead, Scienture is focused on expanding its commercial portfolio and advancing its R&D pipeline.
Read more →Scienture Holdings, Inc. reported a remarkable 216% increase in net revenue for the year ending December 31, 2025, reaching $431,609. The company also achieved a gross margin expansion to 76.8% and improved its operational efficiency. Key developments included the successful launch of Arbli™, which has gained significant traction in the market, and strategic collaborations to enhance access to its products. Despite a net loss attributed to a one-time impairment charge, the company is optimistic about its growth momentum into 2026.
Read more →Scienture Holdings, Inc. has announced the formalization of multiple Group Purchasing Organization (GPO) agreements for its FDA-approved naloxone nasal spray, REZENOPY™, increasing its access to over 5000 healthcare institutions in the U.S. This move is expected to enhance the product's adoption, leveraging the significant commercial opportunity presented by the naloxone market, which totals approximately $141 million annually. REZENOPY™ is positioned as the highest-dose naloxone formulation approved by the FDA and aims to address opioid overdose emergencies across various healthcare settings.
Read more →Scienture Holdings, Inc. provided a commercial update on ARBLI™, the first FDA-approved oral suspension of losartan. The company reported strong access initiatives and financial improvements, projecting continued growth. Additionally, Scienture reaffirmed plans to launch REZENOPY™, an opioid overdose treatment, in Q2 2026, enhancing its product offerings in the market.
Read more →Scienture Holdings, Inc. announced the issuance of a patent for REZENOPY™, a naloxone HCl nasal spray. This patent, effective January 6, 2026, supports the exclusive U.S. commercialization rights held by Scienture. REZENOPY™ is designed to treat opioid overdoses and is the highest dosage naloxone approved by the FDA, enhancing its market potential.
Read more →Scienture Holdings, Inc. has announced the upcoming commercial launch of REZENOPY®, a high-strength naloxone HCl nasal spray approved by the FDA. This product, designed for emergency treatment of opioid overdoses, is expected to be available in early Q2 2026. The company anticipates that REZENOPY® will significantly improve overdose response capabilities due to its higher dosage.
Read more →SCIENTURE Holdings and BlinkRx have announced a strategic collaboration to enhance patient access to Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. This partnership aims to improve the patient experience and adherence to therapy, addressing a significant market need. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026, targeting the substantial U.S. losartan market valued at $245 million annually.
Read more →Scienture Holdings, Inc. will participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9-10, 2025. President Narasimhan Mani will present on December 9, while Executive Chairman Shankar Hariharan will hold one-on-one investor meetings on December 10. The event aims to showcase high-potential small and micro-cap companies.
Read more →Scienture Holdings, Inc. reported strong financial results for Q3 2025, with revenues reaching $590K and gross profits of $575K. The company successfully launched Arbli™, the first FDA-approved ready-to-use liquid formulation of losartan, and expanded its market access significantly. Scienture is also preparing to launch REZENOPY®, a new opioid overdose treatment, in Q1 2026.
Read more →Scienture Holdings, Inc. announced that its product Arbli™ (losartan potassium) has been added to the formularies of major national health plans, enhancing access for over 100 million covered lives in the U.S. This FDA-approved oral suspension offers a convenient alternative to solid dosage forms, potentially benefiting patients requiring liquid medication. The company emphasizes its commitment to improving public health outcomes through this expansion.
Read more →Scienture Holdings, Inc. has announced the commencement of commercial sales for Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. This product aims to provide a convenient alternative for patients requiring liquid formulations. With a significant market opportunity in the U.S. losartan market, Scienture is executing targeted outreach and expanding its distribution agreements to enhance market access.
Read more →Scienture Holdings, Inc. has announced the commercial availability of Arbli™, the first FDA-approved ready-to-use liquid formulation of losartan. This product aims to address the needs of patients with dysphagia, particularly the elderly and children. With an annual market of $256 million, Arbli™ is expected to enhance treatment adherence and safety for hypertension management.
Read more →Scienture Holdings, Inc. announced the full repayment and conversion of outstanding secured convertible debentures into shares of common stock. This agreement with Arena Finance Markets enhances the company's balance sheet by eliminating debt and associated obligations. The move is expected to support Scienture's strategic goals and growth following its recent product launch.
Read more →Scienture Holdings, Inc. has announced the formalization of multiple commercial group purchasing organization (GPO) agreements for its product Arbli™ (losartan potassium) Oral Suspension. This development provides access to over 2500 healthcare institutions, potentially penetrating 20% of the U.S. institutional market. Arbli™ is notable for being the first FDA-approved liquid formulation of losartan, offering a convenient alternative for patients.
Read more →Scienture Holdings, Inc. has secured a significant rebate agreement with a Pharmacy Benefit Manager, enhancing formulary access for its FDA-approved product, Arbli™ (losartan potassium). This agreement aims to cover health plans for over 100 million lives, positioning Arbli™ for rapid market adoption. Arbli™ is notable for being the first ready-to-use liquid formulation of losartan in the U.S., offering a convenient alternative for patients.
Read more →Scienture Holdings, Inc. has announced a registered direct offering of 3,225,000 shares of common stock at $1.20 per share, aiming to raise approximately $3.9 million. This offering is set to close on August 15, 2025, pending customary conditions. Maxim Group LLC is the sole placement agent for this transaction.
Read more →Scienture Holdings, Inc. announced a securities purchase agreement to raise approximately $3.9 million by selling 3,225,000 shares of common stock at $1.20 per share. This offering, expected to close on August 15, 2025, reflects the company's focus on delivering novel specialty products aimed at addressing unmet patient needs. The offering is facilitated by a sole placement agent and is conducted under an effective shelf registration statement with the SEC.
Read more →Scienture Holdings, Inc. has announced the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its distribution center, marking a significant step towards commercialization. The product is the first FDA-approved ready-to-use oral liquid formulation of losartan in the U.S., aimed at treating hypertension and related conditions. The company has also received its first wholesaler order, indicating strong market demand.
Read more →Scienture Holdings, Inc. has successfully secured approximately $1.2 million in bridge funding as part of a larger $3 million raise. This funding will be allocated to support the company's upcoming product launches and pipeline development. The management expresses strong confidence in the company's strategy and future growth potential, highlighting investor support.
Read more →Scienture Holdings, Inc. has announced that it has regained compliance with Nasdaq listing requirements after its common stock maintained a closing bid price above $1.00 for ten consecutive business days. Previously, the company was notified of non-compliance and given a 180-day period to rectify the situation. Executives have expressed their commitment to continue focusing on product launches and improving patient outcomes, particularly with the upcoming release of their FDA-approved product, Arbli™.
Read more →Scienture Holdings, Inc. has announced the termination of its Equity Line of Credit (ELOC) effective May 22, 2025, to refocus on the commercial launch of its first FDA-approved product, Arbli™, which is set for summer 2025. The move is aimed at seeking more favorable financing options to support the company's growth strategy. Arbli™ will be the first and only ready-to-use oral liquid formulation of losartan in the U.S., targeting patients with hypertension and specific diabetes-related conditions. The company expects to launch the product in Q3 2025.
Read more →Scienture Holdings, Inc. has announced a leadership transition as Suren Ajjarapu steps down as CEO and Chairman, roles now taken on by Dr. Shankar Hariharan and Dr. Narasimhan Mani. This change is part of a strategic plan aimed at furthering the company's mission in specialty pharmaceutical development. Both new leaders bring extensive experience from their prior roles and are expected to drive the company toward long-term value creation. Ajjarapu will continue to support the company as an advisor, ensuring continuity during this transition.
Read more →Scienture Holdings, Inc. (NASDAQ: SCNX) announced that the FDA has included two patents for its product, Arbli™, in the Orange Book. This marks a significant regulatory achievement and strengthens the company's position in the pharmaceutical market. Arbli™ is notably the first FDA-approved ready-to-use oral liquid formulation of losartan, designed for patients with hypertension. The listing of these patents supports potential market exclusivity and underscores the company's commitment to innovative therapies.
Read more →Scienture Holdings, Inc. announced the initiation of supply chain activities for its product ArbliTM, an oral suspension of losartan potassium, targeting a commercial launch in July 2025. The product, developed to treat hypertension and related conditions, will be the first ready-to-use oral liquid formulation of losartan approved by the FDA. Scienture has confirmed that their contract manufacturing partner is prepared to produce the necessary quantities. This development highlights the company's commitment to addressing unmet market needs for specific patient demographics.
Read more →Scienture Holdings, Inc. announced the divestiture of its legacy subsidiaries for $5 million to Tollo Health, Inc. This move is part of a strategic plan to sharpen operational focus on the Branded and Specialty Pharma segment through its subsidiary, Scienture, LLC. The company aims to enhance efficiency, reduce redundancies, and redirect resources to its core offerings. Leadership expressed confidence that this decision will drive growth and innovation within the organization.
Read more →Scienture Holdings, Inc. has provided an annual update detailing its transformation into a specialty pharmaceutical company focused on innovative products. The company has received NDA approval for its first in-house product, Arbli, and reported the acquisition of REZENOPY, further diversifying its product offerings. Scienture also outlined strategic efforts in product development and commercial operations geared towards successful product launches in the coming year. Leadership emphasized the commitment to addressing market needs through comprehensive and innovative healthcare solutions.
Read more →Scienture Holdings, Inc. has appointed Michele Rath as the new Senior Vice President and Chief Commercial Officer of Scienture, LLC. Under her leadership, Scienture has established a strategic partnership with Syneos Health through a Master Commercial Services Agreement, aimed at bolstering its commercial operations and market reach. This collaboration is expected to utilize Syneos Health's expertise in sales solutions while gearing up for the launch of two FDA-approved products. Rath’s extensive experience in the industry will be pivotal in driving the company’s commercial initiatives.
Read more →Scienture Holdings, Inc. announced the completion of a draw on its Equity Line of Credit to support the launch of Arbli™, an FDA-approved liquid formulation of losartan. The company will suspend further draws from the ELOC for 30 trading days or until its stock price reaches $10 per share. CEO Suren Ajjarapu emphasized the strategic nature of this decision, indicating confidence in the company's growth prospects. Arbli™ is anticipated to be launched in Q3 2025, addressing unmet needs in hypertension treatment.
Read more →Scienture Holdings, Inc. has announced that the U.S. FDA has approved its New Drug Application (NDA) for SCN-102, branded as ArbliTM, which is a 10 mg/mL oral suspension of losartan potassium. This product is the first FDA-approved ready-to-use liquid formulation of losartan in the United States, aimed at treating hypertension and preventing related risks in patients over 6 years old. Scienture expects to launch ArbliTM commercially in the U.S. market by Q3 2025, with projected market sales based on a growing demand for liquid medication options in this therapeutic category.
Read more →Scienture Holdings, Inc. has announced the commercial launch of REZENOPY, a naloxone HCl nasal spray designed for the emergency treatment of opioid overdoses. The product will be produced in collaboration with Kindeva Drug Delivery, which provides exclusive manufacturing rights. With the FDA's approval granted on April 19, 2024, REZENOPY is the most potent version of naloxone available and aims to enhance public health initiatives in response to rising opioid fatalities. This partnership signifies a strategic effort to increase accessibility to life-saving interventions.
Read more →Scienture Holdings, Inc. announced that Dr. Narasimhan Mani will participate as a speaker at the 8th Annual Conference of The Society for the Study of Xenobiotics in Hyderabad, India, from January 23-25, 2025. He will focus on technology-driven innovations in the pharmaceutical industry and engage in discussions about current trends in drug discovery and development. The event aims to foster knowledge-sharing among professionals in the field and features multiple expert speakers, highlighting the growing importance of discussions around drug development in India.
Read more →Scienture Holdings, Inc. has announced its participation in The Microcap Conference 2025, which will be held from January 28-30, 2025, at the Borgata Hotel in Atlantic City, NJ. The company plans to deliver a corporate presentation and hold one-on-one meetings with institutional and individual investors to discuss recent developments and growth strategies. The conference is recognized as a major event for microcap companies, featuring high-profile speakers and networking opportunities.
Read more →Scienture, LLC, a subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX), has announced the issuance of a new patent for its SCN-102 product, which is a Losartan potassium oral suspension. This patent enhances the company's intellectual property rights and follows an earlier patent, further supporting the product's unique formulation. The NDA for SCN-102 is currently under FDA review, positioning the product as a potentially first market-ready liquid formulation of Losartan, addressing specific patient needs. The company highlights its commitment to developing novel therapies that enhance patient convenience.
Read more →Scienture Holdings, Inc. has announced a private placement of $3 million in 10% secured convertible debentures as part of a larger $12 million offering. The private placement and subsequent equity line of credit agreement, which allows for up to $50 million in funds, is intended for working capital and corporate purposes. The first tranche of the offering was successfully closed on November 25, 2024, but the company has indicated no immediate plans to draw from the equity line of credit. This strategic financing is subject to certain closing conditions.
Read more →TRxADE Health, Inc. is rebranding itself as Scienture Holdings, Inc., with the new ticker symbol SCNX, effective September 23, 2024. This change comes after a business combination with Scienture, LLC, valued at $103 million. The rebranding aims to emphasize the company's transition toward specialty pharmaceuticals while maintaining its operational focus on improving the retail pharmacy experience through its subsidiary Integra Pharma Solutions. The announcement highlights the potential for growth in various therapeutic areas and market segments.
Read more →TRxADE Health, Inc. has successfully completed a business combination with Scienture, Inc., valuing the transaction at $103 million. TRxADE will transition its name to Scienture Holdings, Inc., intending to enhance its focus on specialty pharmaceuticals. The merger aims to leverage the combined expertise to develop innovative products that improve patient care and healthcare outcomes. Post-merger, current Scienture stakeholders are expected to own approximately 83% of the new entity, ensuring strong representation in the new organizational structure.
Read more →TRxADE Health, Inc. has announced a special cash dividend of $1.50 per share for its stockholders. This decision comes following the successful sale of the Company's market platform assets earlier in May 2024. Stockholders of record as of July 19, 2024, will receive the dividend on or around July 24, 2024. The announcement reflects the Company's ongoing financial actions aimed at rewarding its investors.
Read more →TRxADE Health, Inc. has received a notice from Nasdaq regarding its late filing of the Quarterly Report on Form 10-Q for the period ending March 31, 2024. The notice indicates that the company must submit a compliance plan by July 22, 2024, and may be granted an extension of up to 180 days to address the issue. While this notice does not immediately affect the trading of the company's stock, future delays could result in compliance and trading problems.
Read more →TRxADE Health, Inc. has filed its Quarterly Report on Form 10-Q for the period ending September 30, 2023. The company received a notice from Nasdaq about noncompliance for not filing timely but believes it has regained compliance following the report submission. The article also discusses potential risks and uncertainties affecting TRxADE, including legal proceedings and funding challenges.
Read more →Superlatus, Inc. has announced a distribution partnership with Rainforest Distribution Corp., enabling its products to reach over 5,000 retail locations in the Northeast and Mid-Atlantic regions. This collaboration aims to enhance the distribution of Superlatus's Consumer Packaged Goods, including brands like Coolhaus and Spero. The CEO highlighted the partnership as a significant milestone for potential expansion and increased production capability across North America. Rainforest's extensive distribution network will support Superlatus's goals in the high-potential Tri-State area, which houses a substantial consumer base.
Read more →Superlatus, a subsidiary of TRxADE HEALTH, has acquired Spero Foods, a plant-based technology company specializing in dairy and egg alternatives. This acquisition expands Superlatus's consumer packaged goods (CPG) portfolio, adding innovative products that aim to outcompete traditional dairy options. Spero utilizes patented technologies to create sustainable and affordable plant-based food offerings. The collaboration is expected to enhance Spero's market reach and product availability globally.
Read more →Superlatus Inc. is set to revolutionize the $151 billion US snacking market by introducing pulse-based twisted protein snacks under its Brave Robot brand, leveraging innovative food technology from its subsidiary, Sapientia Technology. The snacks promise superior nutritional benefits compared to traditional options, featuring significantly reduced calories, fat, and sodium, while offering increased protein and fiber content. With a strategic focus on better-for-you products targeting schools and institutions, Superlatus aims to capitalize on the growing demand for healthier snacks. The company plans to launch these products in the US by early 2024, following a successful test in Canada.
Read more →TRxADE HEALTH, Inc. has announced the successful closing of its acquisition of Superlatus, Inc., which will help enhance its pharmaceutical and food distribution capabilities. Shareholders of Superlatus received a mix of MEDS common stocks and newly created preferred stocks as part of the deal. Additionally, TRxADE has now regained compliance with the Nasdaq's minimum stockholders' equity requirement due to this merger. This acquisition positions TRxADE to innovate further within the food technology sector.
Read more →TRxADE HEALTH, Inc. has announced an amended merger agreement with Superlatus, Inc., altering the terms of their initial deal. Under the revised agreement, Superlatus's shareholders are set to receive nearly 31 million shares of TRxADE stock at $7.30 per share upon closing. The new terms also introduce rights for existing TRxADE shareholders to receive additional shares. The merger focuses on merging TRxADE's pharmacy services with Superlatus's food technology capabilities.
Read more →Superlatus, Inc. has announced a definitive merger agreement with TRxADE Health, Inc., aimed at creating a strategic platform for the food and healthy snack industries. Under the agreement, Superlatus shareholders will receive shares of TRxADE stock, and the merger is expected to close in late 2023 or early 2024, pending customary conditions. Both companies aim to leverage each other's strengths to capture significant market opportunities in the growing health snacks market. However, the merger faces challenges, including securing necessary approvals and ensuring employee retention during the transition period.
Read more →TRxADE HEALTH, Inc. issued a correction to its earlier press release regarding its planned merger with Superlatus, Inc., which initially miscalculated the number of shares to be exchanged. The corrected announcement clarified that Superlatus shareholders would receive 3,839,176 shares of TRxADE, valued at $58.61 each. This merger aims to create a global food consolidation platform, although the missteps in the initial press release have raised concerns about investor confidence and accuracy moving forward.
Read more →Superlatus, Inc. has signed a binding letter of intent to merge with TRxADE Health, Inc. The agreement involves Superlatus shareholders receiving shares valued at $7.30 per share in TRxADE post-merger. Notably, the merger is contingent on the closing of Superlatus's acquisition of food tech firm Sapientia, which brings important patents for innovative snack products. Together, the companies aim to enhance their market position and develop new high-nutrition food options.
Read more →TRxADE Health, Inc. has announced a 1-for-15 reverse stock split of its common stock, effective June 22, 2023. This action will reduce the number of outstanding shares while maintaining the overall economic value of the company. The reverse stock split may increase the bid price of shares and is aimed at making the stock more marketable to potential investors. TRxADE operates a drug procurement marketplace to enhance the retail pharmacy experience.
Read more →TRxADE HEALTH reported its financial results for Q1 2023, showcasing a gross margin of 69%. Despite this positive margin, total revenues decreased by 31% to $2.2 million compared to the previous year, largely driven by a significant decline in revenue from its Trxade Prime subsidiary. The company saw growth in its main TRxADE platform, with a 4% increase in revenue and registered users growing by 8%, indicating a continued expansion in user engagement. The firm is focused on innovation and sustainable value creation for stockholders amid these challenges.
Read more →TRxADE Health reported a 16% revenue growth for the year ending December 31, 2022, reaching $11.4 million. The company's platform saw an increase in registered members, now totaling approximately 14,400. Notably, revenue from TRxADE Prime surged by 46%. However, the Community Specialty Pharmacy division faced a 29% revenue decline, and TRxADE still recorded a net loss of $3.9 million.
Read more →HEALTH Reports Third Quarter Gross Margin of 58% and Q3 2022 Financial Results Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform FL, November 7, 2022 - TRxADE HEALTH, INC. (NASDAQ: MEDS)("TRxADE" or the "Company"), a health services IT company focuse
Read more →Health Announces Pricing of $1.8 Million Registered Direct Offering FL / ACCESSWIRE / October 4, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurem
Read more →Advisory Board Member and Leading Pharmaceutical Industry Expert, Mr. Jeff Newell, For its Board of Directors FL - (October 3, 2022) - TRxADE HEALTH, INC. (NASDAQ: MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experi
Read more →Notice to TRxADE HEALTH Press Release Reporting Second Quarter Revenue Growth of 73% and Q2 2022 Financial Results Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform HEALTH, INC. (NASDAQ:MEDS) announced today that its press release issued under the he
Read more →HEALTH Reports Second Quarter Revenue Growth of 73% and Q2 2022 Financial Results Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform FL, July 25, 2022 - TRxADE HEALTH, INC. (NASDAQ: MEDS)("TRxADE" or the "Company"), a health services IT company focuse
Read more →HEALTH Reports First Quarter Revenue Growth of 6% and Q1 2022 Financial Results Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform FL, May 9, 2022 - TRxADE HEALTH, INC. (NASDAQ: MEDS)("TRxADE" or the "Company"), a health services IT company focused on
Read more →HEALTH Reports Year End 2021 Financial Results Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform FL, March 28, 2022 - TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE", "TRxADE HEALTH" or the "Company"), a health services IT company focused on digitalizing
Read more →HEALTH, INC. to Participate in the 2022 Virtual Growth Conference by Maxim Group LLC and hosted by M-Vest on 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT FL, March 15, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail ph
Read more →Inc. and Bonum Health (A TRxADE HEALTH Company) Ink Telemedicine Deal To Deploy Deeply Discounted Telemedicine to Uninsured and Under-Insured Consumers FL, February 23, 2022 - TRxADE HEALTH, INC. (NASDAQ: MEDS) an integrated drug procurement, delivery, healthcare platform and
Read more →TRxADE Health forms joint venture SOSRx.com to Expand Medication Accessibility via Manufacturer Partnerships TAMPA, FL, February 15, 2022 TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy ex
Read more →HEALTH to Present at Aegis Virtual Conference FL / ACCESSWIRE / February 9, 2022 / TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription
Read more →HEALTH, INC. Announces Resumption of Modified Stock Repurchase Program FL / ACCESSWIRE / December 13, 2021 / TRxADE HEALTH, INC. (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription
Read more →HEALTH Reports Third Quarter 2021 Financial Results Quarter 2021 Revenue Increased 34.3% over Second Quarter 2021 FL, October 25, 2021 - TRxADE HEALTH, INC. (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug p
Read more →HEALTH Reports Second Quarter 2021 Financial Results 2021 Gross Profit Margin Expands Significantly to 44.3% FL, July 26, 2021 - TRxADE HEALTH, INC. (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procureme
Read more →(Southeastern Grocers, Inc.) and Bonum Health (TRxADE HEALTH Company) Ink Telemedicine Deal FL. July 21, 2021 - TRxADE HEALTH INC. (NASDAQ: MEDS) an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business
Read more →Group, Inc. Announces Name Change to FL / ACCESSWIRE / May 28, 2021 / TRxADE Group, Inc. (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.
Read more →Group Reports Record First Quarter 2021 Financial Results Quarter Revenues Increased 39% to $3.1 Million FL, April 26, 2021 - Trxade Group, Inc. (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement,
Read more →Group to Present at Planet MicroCap Showcase Suren Ajjarapu to Present Wednesday, April 21st, 2021 FL / ACCESSWIRE / April 9, 2021 / Trxade Group, Inc. (NASDAQ:MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procure
Read more →Group Reports Annual Revenue Growth of 130% and Year End 2020 Financial Results Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform FL, March 29, 2021 -- Trxade Group, Inc. (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail
Read more →Group to Present at the Diamond Equity Research Emerging Growth Invitational FL, November 18, 2020 -- Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the Diamond Equity Research Emergin
Read more →Group to Present at the Virtual Fall Investor Summit FL, November 10, 2020 - Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the Virtual Fall Investor Summit, hosted by Investor Summit G
Read more →Group Reports Record Third Quarter 2020 Financial Results Increase 174% to Third Quarter Record of $6.3 Million; Continues Nationwide Platform Expansion FL, October 26, 2020 -- Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform,
Read more →Group Announces Launch of Bonum+ B2B Platform Bundles Telehealth, a COVID-19 Risk Assessment Tool and a PPE Purchasing Tool, through a Secure Mobile Dashboard for Corporate FL, August 11, 2020 - Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and hea
Read more →Group to Report Second Quarter 2020 Results of Operations on Monday, July 27, 2020 FL, July 15, 2020 -- Trxade Group, Inc. (MEDS) an integrated drug procurement, delivery and healthcare platform, announced today that it plans to release its financial results for the second qu
Read more →Group Announces Addition to the Russell MicroCap Index Provides Reminder Regarding Tomorrow's Scheduled Virtual Presentation FL, June 23, 2020 - Trxade Group, Inc. (NASDAQ: MEDS) an integrated drug procurement, delivery and healthcare platform, announced that it has been selec
Read more →Group to Deliver Virtual Presentation on June 24th, 2020 at 11:30 a.m. Eastern time June 15, 2020 8:31 AM EDT FL / ACCESSWIRE / June 15, 2020 / Trxade Group, Inc. (NASDAQ:MEDS) an integrated drug procurement, delivery and healthcare platform, announced today that management wi
Read more →Group, Inc. Withdraws Its Previously Filed FDA Emergency Use Authorization for Rapid COVID-19 Testing Kit in Response To FDA Guidance FL (Access Newswire)- May 7th 2020 - Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, announ
Read more →Group Reports First Quarter 2020 Financial Results 2020 Revenues Increase 46% to $2.2 Million; Drives Net Income Increase of 44% to $0.2 Million FL - May 4, 2020 - Trxade Group, Inc., (NASDAQ: MEDS) ("Trxade" or the "Company"), an integrated telehealth, drug procurement, deliv
Read more →GROUP, INC. Sets Date for 2020 Annual Meeting of Stockholders FL /ACCESSWIRE /April 2nd, 2020/ - Trxade Group, Inc., (Nasdaq: MEDS)("Trxade Group" or the "Company"), an integrated telehealth, drug procurement, delivery and healthcare platform that enables price transparency an
Read more →Group, Inc. Files FDA Emergency Use Authorization for Rapid COVID-19 Testing Kit FL (Access Newswire)- April 1st, 2020 - Trxade Group, Inc. (NASDAQ: MEDS) an integrated drug procurement, delivery and healthcare platform, announces its wholly-owned subsidiary, Integra Pharma So
Read more →GROUP, INC. REPORTS 2019 RESULTS Delivered 2019 annual revenues of $7.43 Million (94.1% increase) Total Adjusted EBITDA of $852,647 (249% increase) Launched next generation of Telehealth Platform ( www.Bonumhealth.com ) Launched Drug delivery platform using our network of ph
Read more →GROUP, INC. Announces Exercise of Overallotment Option by Underwriters FL - (February 24, 2020) - Trxade Group, Inc., (Nasdaq: MEDS)("Trxade Group" or the "Company"), an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased
Read more →GROUP, INC. Announces Closing of Firm Commitment Common Stock Offering FL - (February 18, 2020) - Trxade Group, Inc., (Nasdaq: MEDS)("Trxade Group" or the "Company"), an integrated drug procurement, delivery and healthcare platform that enables price transparency and increased
Read more →GROUP, INC. Announces Uplisting to of $5.2 Million Firm Commitment Public Offering of Common Stock and Effectiveness of Reverse Stock Split Symbol Change to "MEDS" FL - (February 13, 2020) - Trxade Group, Inc., (Nasdaq: MEDS)(OTCQB: TRXD) ("Trxade Group" or the "Company"), an
Read more →Group, Inc's wholly-owned Bonum Health Subsidiary Teams Up with Benzer Pharmacy to launch "Bonum Health Hubs" in Benzer Pharmacies FL (Globe Newswire) - November 21, 2019 - Trxade Group, Inc. (OTCQB: TRXD) ("Trxade" or the "Company"), an integrated pharma supply chain and care
Read more →AND CORPORATE GOVERNANCE COMMITTEE Group, Inc. (the "Company") and Corporate Governance Committee Charter Nominating and Corporate Governance Committee's role is to determine the slate of director nominees for election to the Company's Board of Directors (the "Board") to iden
Read more →Group Generates Record Revenues in Third Quarter of 2019 Growth of 173% to $2.311 Million Income Growth of 94% to $177,853 straight quarter of positive operating income Equity increased to $3.89mil FL (Access wire) - October 31st, 2019 - Trxade Group, Inc. (OTCQB: TRXD) ("Tr
Read more →Group, Inc. (the "Company") Audit Committee of the Board assists the Board in fulfilling its responsibility for oversight of and integrity of the accounting, auditing, and reporting practices of the Company, and such other duties as directed by the Board. The Committee's purpos
Read more →Announces Acquisition of Independent Specialty Pharmacy TAMPA, FL - (October 16th, 2018) - Trxade Group, Inc., (OTCQB: TRXD) a web-based pharmaceutical sourcing and purchasing platform with 9,300 registered independent pharmacy customers that procure over $100M in drug and produ
Read more →Year Ending December 31, 2015 The results of the restatements are as follows: Unaudited Consolidated Balance Sheets as of December 31, 2015 As Reported Adjustment As Restated Current Assets $ 2,027,670 $ (722,099) $ 1,305,571 Current Liabilities $ 1,052,265 $ (13,711) $ 1,0
Read more →Completes Restructuring TAMPA, FL (January 6th 2017) Trxade Group, Inc., (OTCQB: TRXD) a web-based market platform with over 6,700 registered independent pharmacy customers that enables its customers to quickly source and purchase pharmaceuticals, accessories and services from a
Read more →Appointments Independent Director TAMPA, FL (August 24th 2016) Trxade Group, Inc., (OTCQB: TRXD) a web-based market platform with 6,200 registered independent pharmacy customers that enables its customers to quickly source and purchase pharmaceuticals, accessories and services f
Read more →Expands its Board of Directors with Appointment of Independent Director TAMPA, FL (March 18th 2015) Trxade Group, Inc., (OTCBB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers na
Read more →Expands its Board of Directors with Appointment of Independent Director TAMPA, FL (December 23th 2014) Trxade Group, Inc., (OTCBB: TRXD) a web-based pharmaceutical marketplace engaged in promoting and enabling trade among independent pharmacies and large pharmaceutical suppliers
Read more →